- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:02 | OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility | 200 | Newsfile | U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2Scheduled pre-Marketing Authorisation Application meeting with United Kingdom's Medicines and Healthcare products Regulatory Agency... ► Artikel lesen | |
| 25.11. | OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization | 260 | Newsfile | New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today... ► Artikel lesen | |
| 20.11. | OS Therapies to spin off OS Animal Health into a standalone public company | 3 | Seeking Alpha | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 20.11. | OS Therapies plans to spin off animal health unit as public company | 2 | Investing.com | ||
| 20.11. | OS Therapies to Spinoff OS Animal Health into Standalone Public Company | 275 | Newsfile | Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me: Cancer Pioneers' film... ► Artikel lesen | |
| 17.11. | OS Therapies: Aktie fällt nach höherem Quartalsverlust im Zuge von Zulassungsvorbereitungen | 9 | Investing.com Deutsch | ||
| 17.11. | OS Therapies GAAP EPS of -$0.21 misses by $0.08 | 5 | Seeking Alpha | ||
| 17.11. | OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update | 230 | Newsfile | Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting regarding Phase 2b clinical trial of OST-HER2: prevention or delay of recurrent... ► Artikel lesen | |
| 31.10. | OS Therapies Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.10. | OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 336 | Newsfile | New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen | |
| 17.10. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 442 | Newsfile | Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation &... ► Artikel lesen | |
| 10.10. | OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate | 3 | Benzinga.com | ||
| 10.10. | OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma | 306 | Newsfile | 75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p 100% of patients who achieved 12 month event free survival achieved 2 year overall... ► Artikel lesen | |
| 09.10. | OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting | 266 | Newsfile | Overall survival recognized as key efficacy endpoint in osteosarcoma, where no standard of care existsRapporteur highlights potential broader benefits of OST-HER2 in pulmonary and primary osteosarcoma... ► Artikel lesen | |
| 07.10. | OS Therapies to Participate in Fall 2025 Conferences and Events | 307 | Newsfile | Daytime Emmy Awards participation - 2 nomination for 'Shelter Me: Cancer Pioneers' Comparative Oncology documentary that features clinicians, veterinarians and human & canine patients who participated... ► Artikel lesen | |
| 30.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | OS Therapies Updates Sequence Of OST-HER2 Regulatory Submissions, Prioritizes UK MHRA MAA Submission | 1 | RTTNews | ||
| 30.09. | OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update | 261 | Newsfile | Company updates sequence of OST-HER2 regulatory submissions, prioritizing UK MHRA conditional Marketing Authorisation Application (MAA) submission following positive August 2025 Scientific Advice Meeting... ► Artikel lesen | |
| 19.09. | OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT | 274 | Newsfile | New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 49,400 | -0,80 % | Crispr Therapeutics pares loss amid takeover speculation | ||
| IMMUNIC | 0,592 | 0,00 % | EQS-News: Immunic AG: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
26.11.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,360 | +0,74 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,731 | -2,28 % | ANAVEX LIFE SCIENCES CORP zündet - mein Signal blinkt rot! | ||
| ARCTURUS THERAPEUTICS | 6,960 | +1,90 % | Arcturus Raises $2.3M in Seed Funding | ||
| ZEVRA THERAPEUTICS | 7,500 | +0,67 % | Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD | CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,460 | -2,67 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| GEOVAX LABS | 0,380 | -1,07 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| SCILEX | 19,250 | -0,77 % | Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, ... | PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. ("Datavault AI" or the "Company") (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization... ► Artikel lesen | |
| MEIRAGTX | 6,750 | -8,78 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 1,395 | +1,09 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 | Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking... ► Artikel lesen | |
| INVIVYD | 2,275 | +2,48 % | Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness | VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd's proprietary antibody discovery technology platformVBY329... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 6,330 | -2,62 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update | - Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,70 | +36,71 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+2,20 %) liegt der Kurs bei 1,855 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.